glp 1 skin care Patient Buzz: After GLP-1 Weight Loss | The Expert Weighs In On a GLP-1 journey? Don't
Description
GLP-1based therapies are associated with predictable GI adverse effects, most of which are mild to moderate and manageable
Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Gastrointestinal side effects are a little more common in the oral version than in the injectables
Get insights on navigating GLP-1 antagonist shortages and compounds as we navigate demand and supply challenges.
Unlike FDA-approved medications (e.g., Wegovy, Ozempic, Zepbound), compounded alternatives lack agency review for safety, quality, and efficacy
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide
